to the investment project of Wastewater Treatment Plant at Mandalay, Myanmar (Reference to the company’s acquisition of the concessionaire as of 13 August 2015) and other future projects. The project
the restructure of the capital, internal working capital, the investment related to the investment project of Wastewater Treatment Plant at Mandalay, Myanmar (Reference to the company’s acquisition of
the restructure of the capital, internal working capital, the investment related to the investment project of Wastewater Treatment Plant at Mandalay, Myanmar (Reference to the company’s acquisition of
The opinions of the Independent Financial Advisor on the connected transaction (For the purpose of translation only) 0 The opinions of the Independent Financial Advisor on the connected transaction by Thai Wacoal Public Company Limited Presented to Shareholders of Thai Wacoal Public Company Limited Prepared by 8 March 2019 This English report of the Independent Financial Advisor’s Opinions has been prepared solely for the convenience of foreign shareholders of Thai Wacoal Public Company Limited...
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for
ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the operation and delivery of the Company's projects that cause the operation to be delayed than
reducing production cost and also negotiating with customers to review and adjust selling price every quarter. 2.2. Distribution costs for 2018 was in the amount of 4.95 million baht, increased by 1.16
with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change